The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Diprospan in Patients Undergoing Laparoscopic Surgery: a Multi-center Randomized Controlled Trial.

Incisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after laparoscopic surgery, but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. Studies have shown that up to 80% of patients experience postoperative pain following laparoscopic surgery due to inflammation caused by surgical incisions and surrounding tissues, necessitating pharmacological relief. Inflammatory mediators released from the soft tissues around laparoscopic incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.
Numerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. Preemptive incisional infiltration using local anesthetics with corticosteroids which have potent local anti-inflammatory properties may play a key role in preventing or reducing postoperative pain. The objective of this trial is to determine whether preemptive incisional infiltration with ropivacaine plus diprospan is superior to ropivacaine alone in relieving postoperative pain for adults undergoing laparoscopic surgery. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.

开始日期2026-05-30

申办/合作机构

首都医科大学附属北京天坛医院

NCT07626489

/ Not yet recruitingN/AIIT

The Efficacy and Safety of Pre-incisional Infiltration With Ropivacaine Plus Diprospan in Patients Undergoing Video-assisted Thoracoscopic: a Multi-center Randomized Controlled Trial.

Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.
Incisional infiltration is the simplest, safest, and most effective anesthesia method for preventing incision pain after VATS, but even using long-acting local anesthetics, the effectiveness of postoperative analgesia can only last for a relatively short period of time. To improve the efficiency of local incision infiltration in postoperative analgesia, at least two issues need to be addressed: prolonging the duration of analgesia and reducing inflammation of nerve surrounding tissues. Numerous studies have shown that glucocorticoids not only can achieve anti-inflammatory and analgesic effects by inhibiting inflammatory cytokines and inflammatory responses but also can prolong the duration of action of local anesthetics. Preemptive incisional infiltration using local anesthetics with corticosteroids which have potent local anti-inflammatory properties may play a key role in preventing or reducing postoperative pain. The objective of this trial is to determine whether preemptive incisional infiltration with ropivacaine plus diprospan is superior to ropivacaine alone in relieving postoperative pain for adults undergoing VATS. The investigators also compare the effects of the two intervention measures on postoperative pain management, patient safety, and recovery quality.

开始日期2026-05-30

申办/合作机构

首都医科大学附属北京天坛医院

100 项与倍他米松相关的临床结果

登录后查看更多信息

100 项与倍他米松相关的转化医学

登录后查看更多信息

100 项与倍他米松相关的专利（医药）

登录后查看更多信息

5,600

项与倍他米松相关的文献（医药）

2026-07-01·JOURNAL OF PEDIATRIC SURGERY

Topical steroids are effective even in severe phimosis: Evidence from a multicenter cohort

Article

作者: Sierralta, Consuelo ; Arredondo, Catalina ; Brunet, Rodrigo ; Ferreira, Leila ; Astudillo, Jose ; Gonzalez, Gabriela ; Campos, José M ; Concha, Guillermo ; Peña, Mariela ; Torres, Camila ; Montedónico, Sandra ; Ceballos, Vanessa ; Torres, Alberto F

Phimosis is commonly encountered in pediatric surgical practice. Despite evidence supporting topical corticosteroids for phimosis, many clinicians believe they are ineffective in certain subgroups such as severe phimosis or older children, leading to early circumcision. This study aimed to evaluate the effectiveness of topical corticosteroids across different severities and patient characteristics. We conducted a prospective multicenter cohort study across 12 Chilean hospitals between June 2023 and August 2024. Boys under 18 years old with phimosis grades 2 to 5 (Kikiros classification) were treated with 0.05% topical betamethasone twice daily for 8 weeks. Patients were followed up between 8 and 16 weeks. Resolution was defined as improvement to Kikiros grades 0-1. Variables related to treatment outcomes were assessed using univariate and multivariate logistic regression analyses. Out of 386 eligible patients, 235 completed follow-up and were included in the final analysis. Overall treatment success was 68%, with no significant differences across phimosis severity or age groups. The only factor significantly associated with treatment failure was altered preputial skin appearance (success rate: 72% with healthy skin vs. 29% with altered skin; p = 0.007). Other variables, including treatment adherence, age, symptoms, or prior balanitis, were not predictive of treatment failure. Topical corticosteroids are effective for treating phimosis in children, regardless of severity, age or other pre-treatment variables studied. Altered preputial skin appearance may predict lower response rates. These findings support broader implementation of conservative management and may help reduce unnecessary surgical interventions. LEVEL OF EVIDENCE: Level 2b, according to the Oxford Centre for Evidence-Based Medicine (2009).

2026-05-18·International Journal of Ophthalmology

Efficacy and safety of cyclosporine 1% eye drops for the treatment of pediatric blepharokeratoconjunctivitis

Article

作者: Di Grande, Laura ; Giovannini, Mattia ; Danti, Gioia ; Caputo, Roberto ; Mori, Francesca ; Masini, Marzio ; Jeng, Bennie H ; Masi, Valeria ; de Libero, Cinzia ; Simonetti, Gabriele ; Marziali, Elisa

AIM: To evaluate the efficacy and safety of cyclosporine 1% (CsA) eye drops in patients affected by pediatric blepharokeratoconjunctivitis (PBKC). METHODS: This was a retrospective, single arm study of pediatric patients with PBKC. All patients received topical CsA 1% eye drops, administered three times daily for 2mo and then tapered during the third month. In the first treatment week, chloramphenicol and betamethasone eye drops were also given three times daily. Patients were examined at baseline (T0), 4wk (T1), 3mo (T2), and 12mo (T3). At each visit, slit-lamp evaluation of the anterior segment and anterior segment photography were performed. Disease activity and damage were assessed using the modified Hamada bimodal scoring system. Mean PBKC scores across time points were compared using one-way ANOVA, followed by Tukey's HSD post-hoc test. RESULTS: Thirty-six pediatric patients with PBKC were enrolled, six are excluded for incomplete follow-up, leaving 30 patients (11 males, 19 females; mean age 7.71±3.86y) for analysis. The baseline activity score was 1.60±0.62 and decreased significantly at all time points (T1: 0.53±0.51; T2: 0.34±0.76; T3: 0.47±0.86; P<0.001). Damage scores declined by 52% at T1, 53% at T2, and 70% at T3, with significant reductions at T2 and T3 versus baseline (P<0.01). No adverse events occur during the follow-up. CONCLUSION: CsA 1% eye drops effectively control the signs and symptoms of PBKC in pediatric patients and demonstrate a favorable safety profile, supporting their used as a valid therapeutic option in clinical practice.

2026-05-12·ANALYTICAL CHEMISTRY

Real-Time NMR Quantification of Paramagnetic Species during Chemical Reactions

Article

作者: Morris, Gareth A. ; Hamed, Nouran A. ; Nilsson, Mathias ; Golovanov, Alexander P.

Paramagnetic species, such as molecular oxygen, play crucial roles in chemical reactions, yet their concentrations are difficult to measure in real time. Nuclear magnetic resonance (NMR) spectroscopy is powerful for monitoring chemical reactions, but direct quantification requires a NMR-active nucleus with relatively sharp signals, which is not available for many paramagnetic species, like oxygen. ¹H longitudinal relaxation rates (R₁) are sensitive to paramagnetic species and can be used to follow concentrations, but traditional relaxation measurements are often too slow for monitoring kinetics. Here, we introduce paramagnetic species tracking via relaxation-based concentration estimation (PARATRACE), a simple NMR approach that converts routine solvent signals into in situ probes of paramagnetic species. The method exploits the sensitivity of solvent proton R₁ to paramagnetic species by monitoring solvent signal integrals in the regime of partial relaxation between successive scans. Changes in R₁ and, thus, in paramagnetic species can be followed while other reactants are simultaneously monitored at no detriment to time resolution. Using the photodegradation of betamethasone as a model system, we show that oxygen depletion can be quantitatively tracked, in parallel with the main reaction species, throughout the reaction. This approach turns conventional NMR acquisition into a real-time reporter of the paramagnetic environment.

789

项与倍他米松相关的新闻（医药）

2026-06-10

·今日头条

痛风患者福音！这些药物新进展，降酸更精准、更有效

痛风，这个被称为“帝王病”的顽疾，正困扰着越来越多的现代人。传统药物要么副作用大，要么效果不佳，让无数患者在深夜里痛醒。好消息是，医学界在痛风治疗上有了三大突破性进展，为患者带来了新的希望。一、降尿酸治疗：更精准、更有效传统的别嘌醇和非布司他已经陪伴我们多年，但现在有了新的选择。替古利司他（tigulixostat）作为新一代黄嘌呤氧化酶抑制剂，在临床研究中表现亮眼。数据显示，用药12周后，最高剂量组有近三分之二的患者血尿酸达标，而安慰剂组仅有不到3%。目前，该药物正在进行与别嘌醇的“头对头”终极对决，如果成功，将为不耐受现有药物的患者带来曙光。除此之外，多替诺拉德、托匹司他、AR882等一批新药也已进入临床视野。这意味着，未来医生手中的“武器”将更加丰富，可以根据患者的具体情况进行个性化选药。二、难治性痛风：打破免疫排斥瓶颈对于那些常规药物已经失效的“失控性痛风”患者，尿酸酶疗法曾是最后的救命稻草，但人体产生的抗药抗体往往让疗效大打折扣。现在，科学家找到了破解之道——联合免疫调节。研究发现，在使用聚乙二醇化尿酸酶的同时，联合使用小剂量甲氨蝶呤（一种免疫抑制剂），能将12个月的持续应答率从30%翻倍至60%，同时大幅降低输液反应。更进一步的技术是纳米包裹技术（NASP）。这种“特洛伊木马”式的递送系统，能把药物伪装起来，骗过免疫系统，从而实现每月仅需注射一次，就能维持稳定的降尿酸效果，大大提升了患者的生活质量。三、急性发作：生物制剂强势登场对于不能使用秋水仙碱或止痛药（NSAIDs）的患者，急性发作期曾是无解的难题。如今，IL-1通路抑制剂（一种生物制剂）正在改变这一局面。 2026年的最新专家共识指出，虽然这类药物目前主要用于抗炎，但在启动降尿酸治疗时联合使用，能显著降低早期因降酸引起的“溶晶痛”。特别是新型全人源单抗Firsekibart，在针对不适合标准治疗的人群中，其72小时止痛效果不输复方倍他米松，更惊人的是，它能将12周内的复发风险降低90%！这无疑是对频繁发作患者的巨大利好。四、特别提醒：网红药SGLT2抑制剂很多糖尿病患者也在服用SGLT2抑制剂（列净类药物）。虽然研究显示它能轻微降低尿酸，但其降酸幅度非常有限（仅约0.55mg/dl）。切记：它只能作为合并糖尿病痛风患者的“锦上添花”，绝不能替代标准的降尿酸治疗（ULT），否则停药后痛风依然会卷土重来。总结：痛风治疗已进入“精准医疗”时代。从替古利司他的靶向抑制，到尿酸酶的免疫耐受，再到IL-1生物制剂的抗炎升级，未来的痛风治疗将更安全、更高效。如果你正受困于传统药物的副作用或无效，不妨咨询风湿科医生，看看这些新选择是否适合你。

2026-06-10

·中国医学论坛报壹生

专家评述丨靶向白介素-1β的临床价值与二线治疗策略

【摘要】我国痛风患病率升至3.2%。约40%的患者每年急性发作两次以上，传统抗炎治疗达标率不足。绝大多数普通痛风患者对传统抗炎治疗[秋水仙碱、非甾体抗炎药（NSAIDs）及糖皮质激素]耐受良好，约1.9%的患者因传统抗炎治疗受限而“无药可用”。靶向白介素（IL）-1β为难治性痛风提供了精准抗炎的新选择。伏欣奇拜单抗作为国内首个获批的IL-1β单抗，定位于急性痛风发作二线治疗，Ⅲ期临床研究显示其可快速缓解疼痛、显著降低复发风险，48周平均给药约1.6次且安全性良好。本文将探讨伏欣奇拜单抗的二线治疗价值及可及性提升路径。【关键词】痛风；精准抗炎；白介素-1β抑制剂；二线治疗；伏欣奇拜单抗一、疾病负担沉重，传统抗炎治疗面临瓶颈流行病学数据显示，我国痛风患病率已升至3.2%[1]。《柳叶刀》子刊2025年发布的研究更揭示，中国以17.4%的人口承载了全球30%以上的痛风患者，其全因死亡风险增加58%[2]。临床实践中，合并代谢性疾病、心血管疾病或慢性肾脏病（CKD）的痛风患者治疗效果普遍不佳，约40%的患者每年急性发作≥2次。反复发作不仅带来显著的医疗资源消耗，其背后更是持续增加的炎症负荷，使得心血管及肾脏损伤风险随之增加。同时传统抗炎治疗局限明显：秋水仙碱不良反应突出，NSAIDs存在胃肠道及肾损伤风险，糖皮质激素易诱发代谢紊乱，不适合长期使用。痛风患者确诊后1年内出现急性发作的比例约为17.4%[3]。我国痛风患者平均就诊率为61.1%[4]，每年约有408.2万急性发作患者就诊。其中约98.1%的普通痛风患者对传统治疗耐受良好，可通过规范用药有效控制急性发作，但约有1.9%的患者（约7.8万人）因合并心脑血管疾病、肾脏病、糖尿病等，在传统抗炎药（秋水仙碱、NSAIDs 及糖皮质激素）治疗受限的同时，缺乏有效的二线治疗手段，面临“无药可用”的困境[5]。二、基于机制的精准抗炎：NLRP3-IL-1β轴的核心地位痛风本质上是一种由单钠尿酸盐（MSU）结晶沉积所介导的炎症性疾病。MSU结晶激活核苷酸结合寡聚化结构域样受体热蛋白结构域相关蛋白3（NLRP3）炎症小体，促进IL-1β成熟释放，招募巨噬细胞，诱导多种炎症因子表达。IL-1β处于这一炎症通路的关键节点，与慢性炎症状态密切相关。当这一炎症通路在反复发作且传统抗炎治疗受限的患者体内持续激活时，其危害将呈指数级放大。临床数据显示，这类患者面临多重风险：心血管疾病风险升高87%，CKD风险增加可达10倍，糖尿病风险升高99%，关节病致残风险升高506%[2]。对于这部分患者，单纯降尿酸治疗无法阻断上述病理进程——其核心驱动因素正是IL-1β介导的级联炎症反应。因此，在降尿酸基础上，必须靶向IL-1β炎症通路，从源头遏制无菌性炎症，打破“发作—损伤—再发作”的恶性循环。三、伏欣奇拜单抗：定位二线治疗的国内首个IL-1β单抗伏欣奇拜单抗是长春金赛药业自主研发的全人源抗IL-1β单克隆抗体（1类新药），于2025年6月获批上市，荣获“创新药物研发国家科技重大专项”，被列入工信部“国家首批生物制造标志性产品名单”。其适应证明确为二线治疗：适用于对NSAIDs和/或秋水仙碱禁忌、不耐受或缺乏疗效的，以及不适合反复使用类固醇激素的成人痛风性关节炎急性发作患者[6]。关键Ⅲ期临床试验显示：伏欣奇拜单抗给药后6小时快速起效，72小时视觉模拟疼痛评分（VAS）非劣效于复方倍他米松，无激素相关副作用。24周内急性发作风险降低达87%（12周内降低90%），并长效降低超敏C反应蛋白（hs-CRP）[7]。基于Ⅲ期研究48周随访数据，患者在研究期间平均接受了1.6 次伏欣奇拜单抗的给药[8]，提示低频给药有利于提高依从性并降低治疗负担。此外，IL-1β抑制剂可使主要不良心血管事件风险降低15%，在合并CKD的患者中降低18%；炎症控制良好者心血管事件及全因死亡风险进一步降低24%-34%[9-10]。这提示，对于痛风合并心血管疾病或CKD的高风险人群，靶向IL-1β的精准抗炎策略可能同时带来心血管保护和肾脏获益。伏欣奇拜单抗在CKD亚组中已显示出不劣于激素的急性期镇痛疗效和更优的降低复发作用[7-8]，其在降低心肾损伤及死亡风险方面的长期价值值得进一步探索。四、二线治疗的应用场景与分层策略：明确靶向传统治疗受限患者并非所有痛风患者都需要或适合使用IL-1β抑制剂，伏欣奇拜单抗的核心目标人群是约7.8万例传统抗炎治疗受限的患者，此类痛风关节炎患者急性发作严重、合并症多，易反复发作，多器官损害严重，致残率和致死率高，其临床诊断标准可定义为：1.一年之内反复发作≥2次；2.存在临床或影像学诊断的痛风石；3.涉及全身≥2个关节受累或多关节炎；4.VAS评分≥7分。伏欣奇拜单抗作为二线治疗药物，使对传统抗炎治疗受限的“无药可用”患者不再处于治疗盲区，使痛风领域有了清晰的疾病分层管理和完整的诊断治疗路径。五、规范化应用与可及性挑战：指南落地与医保准入尽管IL-1β抑制剂在痛风二线抗炎治疗中的价值日益明晰，但目前临床对其知晓度和掌握程度不足，基层尤为明显。同时，在临床中，精准筛选人群、把握用药时机、规范治疗流程等问题，尚缺乏系统性指引。《痛风抗炎症治疗指南（2025版）》虽已提供了基本框架，但仍有必要制定更精细的二线治疗实践指南，以进一步明确分层评估策略。伏欣奇拜单抗作为一种创新生物制剂，其可及性仍需进一步提高。我国痛风发病年龄呈下降趋势（2003-2022年从42.0岁降至38.9岁）[11]，越来越多青壮年受到痛风困扰，并影响劳动力，其中部分患者恰属传统治疗受限人群。因此，需通过医保准入提高伏欣奇拜单抗的可及性，惠及真正需要二线治疗的患者。六、展望：从二线到更广泛的炎症性疾病伏欣奇拜单抗可抑制炎症级联反应，理论上对于全身型幼年特发性关节炎（sJIA）、非感染性葡萄膜炎、结缔组织病相关间质性肺病等以炎症为关键环节的疾病，具有一定的治疗潜力。伏欣奇拜单抗治疗sJIA的Ⅱ期试验结果已发表于《风湿病与治疗》[12]，其他适应证相关的临床试验也在积极推进中。同时，炎症本身具有双重属性，它是防御和清除“侵略者”的重要保护机制，但过度的炎症反应则会造成组织损伤。因此，临床关键在于精准抗炎——精准筛选适宜患者、精准把握用药时机。伏欣奇拜单抗明确的二线治疗地位决定了它应聚焦于真正因传统抗炎治疗受限而“无药可用”的难治性患者，而非盲目扩大使用。精准二线治疗，是临床实践的核心问题，也是未来持续探索的方向。参考文献[1] 中华预防医学会风湿病预防专业委员会.痛风抗炎症治疗指南（2025版）.中华风湿病学杂志,2025,29(11): 721-736.[2] Im PK, et al. Hyperuricemia, gout and the associated comorbiditiesin China: findings from a prospective study of 0.5 million adults[J]. Lancet Reg Health West Pac, 2025;58:101572.[3] Finnikin S, et al. Cohort study investigating gout flares and management in UK general practice[J]. BMC Prim Care, 2023,24(1):246.[4] 刘海俊,等.广州市南郊农村痛风性关节炎患者疾病认知度调查[J]. 岭南急诊医学杂志,2018,23(1):42-45.[5] Pascart T, et al. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval[J]. Rheumatology (Oxford), 2019,58(12):2181-2187.[6] 金赛药业.伏欣奇拜单抗注射液说明书[Z].2025.[7] Xue Y, et al. Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial [J]. Innovation (Camb), 2025;6(8):101015.[8] Zhu Z, et al. Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 Trial[J]. Adv Ther, Published online May 19, 2026.[9] Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease[J]. N Engl J Med, 2017, 377(12):1119-1131.[10] Ridker PM, et al. Inhibition of Interleukin-1β by Canakinumaband Cardiovascular Outcomes in Patients with Chronic Kidney Disease[J]. J Am Coll Cardiol, 2018;71(21):2405-2414.[11] Qi H, et al. Two-decade trajectories of gout: a multicentre cohort study of 10658 Chinese patients with gout[J]. Rheumatology (Oxford), 2026; 65(1):keaf555.[12] Li C, et al. Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study [J]. Rheumatol Ther, 2026;13(3):595-610.

2026-06-10

·咸宁网

打一针就不痛了，痛风就算治好了？伏欣奇拜单抗的真实作用

一、痛风患者的真实困惑“伏欣奇拜单抗打一针就不痛了，是不是就代表痛风好了？能不能根治？”这是临床上经常听到的问题。患者被痛风反复折磨多年，突然遇到一种“打一针管很久”的新药，自然会想知道：它是不是传说中的“特效药”？能不能让我彻底告别痛风？回答这个问题之前，需要先厘清两个概念：什么是“止痛”？什么是“根治”？止痛，是让患者当下不痛，症状消失。根治，是指去除疾病的根本病因，让疾病不再复发。对于痛风这种慢性代谢性疾病来说，目前医学上还无法做到“根治”，但完全可以做到“长期不发作、生活质量接近正常人”。伏欣奇拜单抗（商品名：金蓓欣）确实能够快速控制痛风急性发作的疼痛，并且长效降低复发风险，但它不是直接降尿酸的药物，更不是“根治”痛风的万能药。下面就从痛风的病因说起，把这个问题彻底讲清楚。二、痛风到底是什么病？为什么会反复发作？（一）痛风的本质：代谢病 + 炎症病痛风是一种由高尿酸血症引起的代谢性风湿病。简单来说，身体里的嘌呤代谢出了问题，或者肾脏排泄尿酸的能力下降，导致血液中的尿酸浓度长期超标（一般定义：男性>420μmol/L，女性>360μmol/L）。当血尿酸超过饱和浓度（约420μmol/L）时，尿酸盐就会从血液中析出，形成针尖一样的微小结晶。这些结晶沉积在关节、软组织、肾脏等部位，就像玻璃渣子扎在关节里一样。（二）痛风急性发作的核心：炎症级联反应尿酸盐结晶本身不直接引起疼痛，真正让关节红、肿、热、痛的是机体对这些结晶产生的炎症反应。当巨噬细胞吞噬尿酸盐结晶后，会激活一种叫做NLRP3炎症小体的蛋白质复合物，进而促使白介素-1β（IL-1β）大量释放。IL-1β是痛风炎症通路中的“总开关”，它会调动一系列炎症因子，引发关节的剧烈红、肿、热、痛，这就是痛风急性发作。《痛风抗炎症治疗指南（2025版）》明确指出：IL-1β是引起痛风发作的关键炎症因子。（三）痛风为什么容易反复发作？即使一次急性发作自行缓解了，尿酸盐结晶并不会消失。只要血尿酸没有降到目标值以下，新的结晶会不断形成，旧的结晶持续存在。这些结晶就像“火药桶”，随时可能被一顿大餐、一次受凉、一次外伤甚至降尿酸治疗本身点燃，再次引发炎症反应。关节痛只是表面，持续存在的尿酸盐结晶和低度慢性炎症，才是痛风反复发作、逐渐损伤关节和脏器的真正元凶。三、伏欣奇拜单抗是什么？它是“止痛药”吗？（一）作用机制：精准阻断炎症因子，而非麻痹神经很多人把伏欣奇拜单抗简单理解为“止痛药”，这是一种误解。传统止痛药（如布洛芬、双氯芬酸、塞来昔布）属于非甾体抗炎药，它们通过抑制环氧合酶（COX）来减少前列腺素的合成，从而减轻疼痛和炎症。但它们对痛风核心的炎症因子IL-1β没有直接阻断作用。伏欣奇拜单抗（通用名：伏欣奇拜单抗，商品名：金蓓欣）是一种IL-1β抑制剂，属于全人源单克隆抗体生物制剂，是中国首款且目前唯一获批用于成人痛风性关节炎急性发作的1类创新药。它的作用是：特异性结合并阻断IL-1β，不让它去激活下游的炎症通路。这相当于在炎症的“总开关”上直接按下了停止键。（二）它不只是“止痛”，更是一种长效抗炎和复发预防策略伏欣奇拜单抗的半衰期长达25.5~30.8天，单次皮下注射200mg后，可以在体内持续作用数周。III期注册临床研究显示：给药后6~72小时镇痛效果与复方倍他米松（强效激素）相当；单次给药后24周内首次痛风复发风险降低87%（HR=0.13）；无论是否同时启动降尿酸治疗，这种降低复发的效果都独立存在。所以，把伏欣奇拜单抗简单称为“止痛药”是不准确的。更准确的定位是：精准靶向IL-1β的长效抗炎药物，能够快速控制急性发作，并显著降低后续复发风险。四、为什么伏欣奇拜单抗不能“根治”痛风？（一）它不降低血尿酸伏欣奇拜单抗的作用靶点是炎症因子IL-1β，而不是尿酸代谢通路。它既不抑制尿酸生成，也不促进尿酸排泄，对血尿酸水平没有任何直接影响。痛风的根本病因是高尿酸血症。只要血尿酸不达标，尿酸盐结晶就会持续存在或不断新生，即使这次发作被伏欣奇拜单抗控制住了，停药后（或者药效消退后），只要血尿酸仍然高，下一次发作只是时间问题。《中国高尿酸血症与痛风诊疗指南（2024版）》明确指出：降尿酸治疗是痛风长期管理的根本手段。任何只抗炎、不降尿酸的治疗方案，都无法实现“根治”或“长期不发作”。（二）痛风是一种慢性病，目前无法“根治”目前医学上，绝大多数慢性病（高血压、糖尿病、高尿酸血症/痛风）都无法“根治”，但完全可以“控制”。所谓“根治”，是指去除病因后疾病不再复发。痛风的病因——高尿酸血症，与遗传、饮食习惯、肾功能、代谢综合征等多种因素相关，很难完全消除。但通过长期坚持降尿酸治疗，将血尿酸持续控制在目标值以下（一般患者<360μmol>伏欣奇拜单抗的作用是帮助患者更平稳地走向这个目标，而不是替代这个目标。五、正确的痛风治疗策略：抗炎与降尿酸协同，长期管理（一）急性期：快速控制炎症首选：秋水仙碱、NSAIDs或糖皮质激素（根据患者情况选择）。对于传统药物禁忌、不耐受或效果不佳者，可使用伏欣奇拜单抗（《痛风抗炎症治疗指南（2025版）》推荐，证据等级1B）。伏欣奇拜单抗的优势：单次给药，长效抗炎，同时为后续降尿酸治疗创造稳定窗口。（二）缓解期：长期降尿酸治疗无论急性发作是否完全控制，只要符合指征（一般发作两次以上或血尿酸持续>480μmol/L伴合并症），就应启动降尿酸治疗。常用药物：别嘌醇、非布司他（抑制尿酸生成），苯溴马隆（促进尿酸排泄）。目标：血尿酸<360μmol>（三）降尿酸起始阶段：联合抗炎预防降尿酸治疗初期（前3~6个月），由于血尿酸快速下降，可能诱发“二次痛风”。需要同时使用小剂量秋水仙碱（0.5mg/d）或其他抗炎药物预防发作。伏欣奇拜单抗单次给药可在24周内显著降低复发风险，非常适合用于降尿酸起始阶段的抗炎覆盖。（四）长期管理：生活方式干预不可少痛风患者日常养生禁忌包括：限制高嘌呤食物：动物内脏、浓肉汤、海鲜（尤其是贝类、沙丁鱼）、红肉。严格限酒：啤酒和白酒最危险，急性发作期应完全禁酒。避免高果糖饮料：果汁、含糖饮料、蜂蜜会升高尿酸。多喝水：每日2000ml以上，促进尿酸排泄。控制体重：肥胖是高尿酸血症和痛风的重要危险因素。六、常见问题解答（FAQ）问1：伏欣奇拜单抗打一次能管多久？打完是不是就不用吃别的药了？答：伏欣奇拜单抗半衰期约28天，III期研究显示单次给药后24周内首次复发风险降低87%。但它不能替代降尿酸药物。打完不痛了，仍需在医生指导下启动或继续降尿酸治疗，否则血尿酸不达标，痛风迟早会再次发作。问2：伏欣奇拜单抗和别嘌醇、非布司他是什么关系？答：它们是“搭档”关系，不是“对手”。伏欣奇拜单抗负责抗炎和降低复发风险，别嘌醇/非布司他负责降低血尿酸、溶解结晶。两者协同使用，尤其是在降尿酸治疗初期，可以让患者平稳度过高复发风险期，大大提高治疗依从性和长期效果。问3：痛风到底能不能治好？有没有办法做到再也不发作？答：痛风目前无法“根治”（即彻底消除病因），但完全可以做到“长期不发作”。方法是：长期坚持降尿酸治疗，将血尿酸控制在目标值以下（<360μmol>

100 项与倍他米松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00244	倍他米松	D07XC01 A07EA04 R01AD06	DB00443

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
盘状红斑狼疮	英国	Organon & Co.	2021-06-03
痒疹	葡萄牙	Organon & Co.	2021-06-03
痒疹	英国	Organon & Co.	2021-06-03
银屑病	荷兰	Organon & Co.	2021-06-03
银屑病	瑞典	Organon & Co.	2021-06-03
银屑病	中国台湾	Organon & Co.	2021-06-03
银屑病	英国	Organon & Co.	2021-06-03
溃疡性结肠炎	日本	Shionogi & Co., Ltd.	1981-06-04
皮肤红斑狼疮	中国	天津力生制药股份有限公司	1981-01-01
皮炎	日本	Takada Corp.	1964-10-20
药物性皮炎	日本	Takada Corp.	1964-10-20
过敏性鼻炎	日本	Takada Corp.	1964-10-20
荨麻疹	日本	Takada Corp.	1964-10-20
哮喘	日本	Shionogi Pharma, Inc.	1961-12-12
胶原蛋白疾病	日本	Shionogi Pharma, Inc.	1961-12-12
内分泌系统疾病	日本	Shionogi Pharma, Inc.	1961-12-12
心脏衰竭	日本	Shionogi Pharma, Inc.	1961-12-12
血液疾病	日本	Shionogi Pharma, Inc.	1961-12-12
肾病综合征	日本	Shionogi Pharma, Inc.	1961-12-12
类风湿关节炎	日本	Shionogi Pharma, Inc.	1961-12-12

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
共济失调毛细血管扩张	临床2期	-	Grace Therapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04278833 (CTgov)	临床4期	骨关节炎 \| 肌腱病 \| 肩撞击综合征	165	Corticosteroid (Particulate Corticosteroid Injection - Shoulder Injection Site)	製顧鑰鬱膚鬱鹹糧願築(顧夢願獵選夢範壓觸築) = 構願積醖構繭窪壓築繭鬱夢壓夢網願積鬱築齋 (遞壓築製廠願廠夢淵願, 2.1) 更多	-	2025-02-12
				Corticosteroid (Particulate Corticosteroid Injection - Hip Injection Site)	製顧鑰鬱膚鬱鹹糧願築(顧夢願獵選夢範壓觸築) = 餘繭鬱獵憲衊遞廠積膚鬱夢壓夢網願積鬱築齋 (遞壓築製廠願廠夢淵願, 3.1) 更多
NCT04900220 (CTgov)	临床4期	阿蒂斯反应 \| 扳机指病症	66	Betamethasone (Betamethasone)	醖艱鹹製鏇襯鏇選製選 = 鹹獵夢鬱壓鏇選構淵醖糧窪淵選構鏇網簾廠艱 (遞鏇壓製鏇憲製艱膚餘, 襯鬱觸構窪衊遞選選鹽 ~ 蓋壓網繭襯鏇廠鹽觸選) 更多	-	2023-06-23
				Methylprednisolone (Methylprednisolone)	醖艱鹹製鏇襯鏇選製選 = 壓觸構築憲積顧蓋鬱觸糧窪淵選構鏇網簾廠艱 (遞鏇壓製鏇憲製艱膚餘, 糧觸鏇鏇衊簾鬱齋顧簾 ~ 艱顧襯鏇餘製繭糧廠艱) 更多
NCT02469519 (Pubmed \| Am J Obstet Gynecol MFM)	N/A	胎膜早破	194	Booster antenatal corticosteroids	蓋廠鏇襯範鏇糧糧網積(簾選遞廠醖糧構獵蓋簾) = 壓繭獵網繭鏇繭糧艱網積夢膚網醖願範淵遞繭 (襯窪夢醖簾壓餘鬱憲選 ) 更多	不佳	2023-02-13
				Placebo	蓋廠鏇襯範鏇糧糧網積(簾選遞廠醖糧構獵蓋簾) = 製鹽築積獵夢簾醖鑰夢積夢膚網醖願範淵遞繭 (襯窪夢醖簾壓餘鬱憲選 ) 更多
NCT02038634 (CTgov)	临床4期	亚急性甲状腺炎	16	betamethasone (Unguided Injections)	鏇構觸積鏇觸鑰顧範醖(蓋鑰繭壓艱範願夢襯鹹) = 構簾鏇鹽壓遞構顧壓鏇築壓淵壓淵範構鬱遞鏇 (遞齋構構糧簾鏇壓鏇衊, 選醖廠觸窪餘窪繭壓艱 ~ 築範範齋顧簾壓鬱簾醖) 更多	-	2022-12-28
				Ultrasound+betamethasone (Ultrasound-guided Injections)	鏇構觸積鏇觸鑰顧範醖(蓋鑰繭壓艱範願夢襯鹹) = 醖衊鹽願齋壓範範顧願築壓淵壓淵範構鬱遞鏇 (遞齋構構糧簾鏇壓鏇衊, 憲襯觸網鏇選簾積鹹築 ~ 廠鹽範網窪襯鑰鬱壓餘) 更多
NCT04420572 (CTgov)	N/A	大转子疼痛综合征	63	ozone injection (Ozone Injection Group)	構繭網廠淵獵構築膚憲(艱夢繭襯膚顧顧淵觸製) = 選鹽窪壓築廠製願夢遞製襯艱壓選製衊鬱繭積 (鹽窪繭構構鹹繭艱壓範, 1.06) 更多	-	2021-10-21
				betamethasone (Steroid Injection Group)	構繭網廠淵獵構築膚憲(艱夢繭襯膚顧顧淵觸製) = 餘製蓋艱願鹹糧艱餘構製襯艱壓選製衊鬱繭積 (鹽窪繭構構鹹繭艱壓範, 0.95) 更多
NCT02749799 (CTgov)	临床4期	斑块状银屑病	45	betamethasone dipropionate+DFD-01	範鏇鹹夢淵範積繭簾餘(獵鹽壓鑰廠憲鹽選網觸) = 觸選顧鑰構網夢製鬱遞齋衊夢淵餘簾網衊鏇鹹 (夢遞廠廠蓋獵蓋衊衊醖, 0.77) 更多	-	2020-10-05
NCT00669383 (CTgov)	N/A	-	85	A (Betamethasone) (A (Betamethasone))	艱淵網醖襯願衊鏇艱鏇(蓋鏇繭鏇膚蓋鏇憲顧鹽) = 簾夢積製鬱簾遞顧襯範窪製鑰構鑰積醖餘繭繭 (築窪鹹鬱鑰衊餘製襯簾, 8.8) 更多	-	2019-02-22
				Placebo (B (Placebo))	艱淵網醖襯願衊鏇艱鏇(蓋鏇繭鏇膚蓋鏇憲顧鹽) = 淵醖淵餘廠範艱窪構網窪製鑰構鑰積醖餘繭繭 (築窪鹹鬱鑰衊餘製襯簾, 7.9) 更多
NCT01222247 (ALPS, CTgov)	临床3期	怀孕 \| 呼吸窘迫综合征 \| 早产	2,831	betamethasone (Betamethasone)	鬱網繭選糧糧鏇構鏇齋 = 鹽鏇膚壓壓鑰艱淵鏇網夢顧鑰鏇選壓遞積積鑰 (願繭鑰鬱艱鏇壓廠構製, 顧襯製淵顧衊願餘齋窪 ~ 艱壓襯鬱遞觸糧遞構遞) 更多	-	2019-01-30
				Placebo (Placebo)	鬱網繭選糧糧鏇構鏇齋 = 製簾艱鬱繭顧範鹽鏇網夢顧鑰鏇選壓遞積積鑰 (願繭鑰鬱艱鏇壓廠構製, 鹹夢鏇獵糧構選積膚廠 ~ 製鏇繭壓築構夢顧艱顧) 更多
NCT00669383 (Pubmed \| J Pediatr)	N/A	早产儿疾病	-	Rescue Antenatal Steroids	鹹選廠糧糧鑰憲遞獵壓(鏇繭顧簾鹽製廠糧簾醖) = 餘製選網遞衊選遞衊製鬱鏇顧廠築齋製憲鹽網 (獵範遞遞鑰餘繭積築遞 )	-	2017-02-01
				Placebo	鹹選廠糧糧鑰憲遞獵壓(鏇繭顧簾鹽製廠糧簾醖) = 襯觸鹽選簾鏇鹹膚網鏇鬱鏇顧廠築齋製憲鹽網 (獵範遞遞鑰餘繭積築遞 )
NCT01222247 (Pubmed 1 \| Pubmed 2 \| N Engl J Med)	临床3期	早产	2,831	Betamethasone	獵網艱繭繭醖壓積觸憲(製網願糧鏇餘餘蓋艱艱) = 鹹鹽淵齋遞憲壓構糧襯築鑰遞艱積鹽觸選艱糧 (鏇膚積製廠網網鏇鏇繭 )	-	2016-04-07
				Placebo	獵網艱繭繭醖壓積觸憲(製網願糧鏇餘餘蓋艱艱) = 夢構糧遞獵膚鹹廠憲醖築鑰遞艱積鹽觸選艱糧 (鏇膚積製廠網網鏇鏇繭 )